FORMOSA PHARMACEUTICALS , INC
Area: CDMO
Booth No: M318
Website: https://www.formosapharma.com
Exhibitor Profile
Formosa Pharmaceuticals (6838.TW), founded in 2010, is a clinical stage biotechnology company with assets in ophthalmology, oncology.
Our Business Development Goals:
* APP13007 (Ophthalmic Nanosuspension for Inflammation and Pain after Ocular Surgery) [US FDA approved]
* TSY-0110 (ADC biosimilar of Kadcyla (T-DM1)) [Late-preclinical stage]
* APNT® Nanoparticle Formulation Platform [Druggability validated]
* Co-development or strategic in-license ADC novel agents and ophthamology assets
Brands
BYQLOVI™
Video
Exhibit Products
-
TSY-120 - Enhertu (T-DXd) Biosimilar
-
TSY-310 - A Next-Generation Novel Bispecific ADC
-
TSY-110 - Kadcyla (T-DM1) Biosimilar
-
APNT Nanoparticle Formulation Platform
-
APP13007 - Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery
-
APP13002 - Infectious Eye Diseases Treatment
Exhibitor Press Release
- Formosa Pharma and Rxilient Inc Deal to Commercialize APP13007 for ASEAN markets 2026-03-27
- Formosa Pharma Partners with Samil to Commercialize Ophthalmic Treatment for Ocular Surgery 2026-03-27
- Formosa Pharma Licenses Ophthalmic Suspension to Arrotex for Post-Surgery Pain & Inflammation 2026-03-27
Exhibitors you may be interested in
Highest Rated
